Navigation Links
NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinson's Disease
Date:6/1/2010

NESS ZIONA, Israel, June 1, 2010 /PRNewswire/ -- NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611. ND0611, a proprietary drug formula administered via a dermal patch, is designed to maintain continuous therapeutic levodopa concentrations for improving the treatment of Parkinson's disease.

ND0611 increases levodopa bioavailability and extends its effects by administering a novel pharmaceutical. Previous animal studies found that ND0611 modified levodopa pharmacokinetics by (i) increasing levodopa plasma half-life and area-under-the-curve (AUC), (ii) maintaining levodopa plasma concentrations in a typical therapeutic range, and (iii) extending dopaminergic stimulation in the brain. ND0611's mode of action involves an under-exploited levodopa metabolic pathway and has the potential for markedly improving clinical benefits from levodopa (the most effective drug for Parkinson's disease).

This Phase 1 study was conducted in healthy volunteers with the purpose of measuring the safety and tolerability of ND0611 at different doses. Further analysis will be completed to determine the pharmacokinetic profile of levodopa in plasma. The company expects to present the results of this phase 1 study in the second half of 2010.

"The completion of this first step in the clinical development of ND0611 marks an important milestone in the path to develop a new therapeutic alternative for Parkinson's disease patients," said Oded S. Lieberman, PhD, NeuroDerm's Chairman and CEO. "While constant levodopa plasma concentrations achieved through continuous levodopa infusion have been shown to bring significant benefit to Parkinson's patients, these options are generally impractical. In contrast, ND0611
'/>"/>

SOURCE NeuroDerm Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
2. MedAvante Opens Moscow Office and Successfully Completes First Centralized Ratings Assessment
3. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
4. Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc.
5. Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
6. Phonak Successfully Hosts Hearing Care for Adults 2009 Conference
7. Tamaulipas Comparative Wound Healing Test Treatment Successfully Concluded
8. DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm
9. Guided Delivery Systems, Inc. Successfully Treats First Patient with Mitral Regurgitation
10. Hoviones TwinCaps(R) Inhaler Delivers Successfully in Phase III Clinical Trials for Influenza
11. American University of Beirut Medical Team Successfully Performs First Artificial Heart Implant in Lebanon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)...  (Booth #7309, North Hall) — Dicom Systems ... DCMSYS Interface WebBridge, at the 100th annual RSNA Meeting ... Chicago, Illinois . ... for medical facilities of any size, WebBridge allows any ... non-standard data (e.g. JPEG, TFF, PDF, TXT, etc.) to ...
(Date:11/27/2014)... 2014 Hovione announced today it ... with the U.S. Food and Drug Administration (FDA). This ... improved drug delivery options for established drugs. ... formulation using a new patented crystalline base form of ... prescribed oral antibiotics for acne. Currently, there are no ...
(Date:11/26/2014)... 26, 2014  Perrigo Company plc ("Perrigo") (NYSE: ... "Quality Affordable Healthcare Products®," today announced the closing of ... sale of 6,809,210 ordinary shares at a public offering ... of the option to purchase up to an additional ... Barclays Capital Inc., as representatives of the several underwriters. ...
Breaking Medicine Technology:Dicom Systems Announces WebBridge Interface at RSNA 2014 2Hovione Files its First Investigational New Drug Application With the FDA 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4
... the Potential Utility of Modigene,s CTP Technology ... ... Va., Sept. 24 Modigene Inc. (OTC,Bulletin Board: MODG) today reported ... journal Endocrinology showing that,erythropoietin (EPO) linked to Modigene,s carboxyl terminal peptide ...
... 24 Iodine has been used as an,antimicrobial ... about molecular,iodine yet many women suffering from Fibrocystic ... may soon yield an effective,nonhormonal treatment. While ... market, all,available hormonal therapies have significant adverse events. ...
Cached Medicine Technology:Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 2Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 3Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 4Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease 2
(Date:11/28/2014)... Novatus, a leading provider of ... which provides customers with greater reporting capabilities, more ... “As we continue to evolve and grow the ... and improved performance in response to requests from ... “With the enhancements that we have made to ...
(Date:11/28/2014)... Miami's Plastic Surgery of the Face recently ... Dr. Jeffrey Epstein is excited to offer patients ... platform, the site is uniquely designed for easing viewing ... 75% of all prospective rhinoplasty patients research upcoming procedures ... on with smartphones, tablets, and laptops, as well as ...
(Date:11/28/2014)... Celebration can quickly turn to tragedy if popular turkey ... Over the last decade, more than 141 serious fires ... turkey fryers, according to the U.S. Consumer Product Safety ... who tried to deep fry the turkey indoors, which ... Arthur Sanford, a burn surgeon at Loyola University Health ...
(Date:11/28/2014)... PA (PRWEB) November 28, 2014 An inventor ... curing light on a patient’s filling and it was almost ... more ergonomic curing light," she said. , The patent-pending Access ... It eases access to areas of the mouth, as well ... promotes efficiency and safety. Easy to use and clean, it ...
(Date:11/28/2014)... 2014 UniWigs.com, a leader in the wig industry, ... to the next Monday. This promotion features: , ... items up to 70% off (no coupon code needed), ... Free shipping on orders over $49 , Visit http://www.uniwigs.com ... from Nov. 28th to Dec. 1st and the first 100 shoppers ...
Breaking Medicine News(10 mins):Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Top Rhinoplasty Surgeon Launches Innovative Website 2Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2
... cancer surgeons regularly confer with plastic surgeons prior to surgery, ... a new study led by researchers at the University of ... breast cancer treatment can vary widely ranging from small ... the type of care a woman receives when it comes ...
... ,PHOENIX, Ariz. Aug. 31, 2010 The first study ... how they affect cell growth has identified two potential anti-cancer ... Genomics Research Institute (TGen) published this month in the journal ... aggressive cancer lesions that occur most frequently in the bones ...
... exposed to violence in their community are at an increased ... asthma or any cause, according to new research from the ... violence has been linked to more symptoms in pediatric asthma ... a longitudinal study showing a connection in an adult population ...
... cancer deaths worldwide, and the prognosis is generally poor, ... one type of lung cancer, adenocarcinoma, has been increasing ... in tumor cell biology that result in a more ... tissue) that have been completely surgically removed may help ...
... Portugal: Hundreds of millions of euros are being ... consulting community pharmacists rather than going straight to their ... 1 September) at the annual conference of the International ... million was freed up in one year for other ...
... Selenium effects may vary according to individual,s characteristics. ... cancer. According to results of a study published ... Prevention , a journal of the American Association for Cancer ... cancer. "The lower the levels of selenium, the ...
Cached Medicine News:Health News:Surgeons impact whether a woman gets breast reconstruction, U-M study finds 2Health News:TGen finds therapeutic targets for rare cancer in children 2Health News:Violence in inner city neighborhoods contributes to trouble with asthma 2Health News:Tumor budding identified as predictor for unfavorable outcome in lung cancer 2Health News:Health advice from pharmacists saves hundreds of millions of euros 2Health News:Health advice from pharmacists saves hundreds of millions of euros 3Health News:Increasing selenium intake may decrease bladder cancer risk 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 12 mm....
Medicine Products: